Tag: Pp405

Affecting more than 80% of men and 40% of women, androgenetic alopecia is a widespread concern [1.5.4]. A promising molecule, PP405, has generated significant buzz, leading many to ask: **Is PP405 available in the market?** As of September 2025, the answer is no; it remains an investigational drug in clinical trials [1.4.1, 1.4.2].

As of late 2025, PP405 is still undergoing Phase 2a clinical trials for hair loss, meaning the answer to 'Is PP405 available to buy?' is a definitive no, and any products claiming otherwise are likely scams. This novel topical treatment offers a new, non-hormonal approach to reactivating dormant hair follicles.

Clinical trials for new medications can often take 5 to 10 years, and for the highly anticipated hair loss treatment PP405, the timeline for availability remains a critical question for many. Developed by Pelage Pharmaceuticals, this novel topical treatment is still years away from reaching pharmacy shelves.

According to the American Academy of Dermatology, over 50 million Americans are affected by androgenetic alopecia, the most common form of hair loss. As researchers seek more effective solutions, the question of 'what is the new peptide for hair growth?' has emerged as a topic of significant interest in regenerative medicine.